Model Medicines

Model Medicines is an AI-first biotechnology company based in San Diego, California, discovering and developing first-in-class small-molecule drugs by targeting fundamental disease mechanisms it calls biological choke points. Its end-to-end GALILEO AI engine spans drug design, target discovery, and preclinical development, supported by specialized models including AmesNet for regulatory-grade toxicology prediction and ChemPrint for chemical property prediction. Lead programs target RdRp Thumb-1 (a conserved allosteric pocket on viral RNA-dependent RNA polymerase) and BRD4, with lead assets MDL-001, a broad-spectrum oral antiviral candidate, and MDL-4102. Surfaced as a portfolio company of 8vc and added to the API Evangelist network. As of this enrichment pass Model Medicines publishes no public API, developer portal, SDK, or documentation surface; its AI platform is used internally for drug discovery.

Model Medicines is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Drug Discovery, Artificial Intelligence, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub
6.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyDrug DiscoveryArtificial IntelligencePharmaceuticalsSmall MoleculesLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 6.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 1.8 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.9 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/model-medicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Model Medicines Domain Security

TLSv1.3 · HSTS · DNSSEC · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: model-medicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/model-medicines.png
name: Model Medicines
description: Model Medicines is an AI-first biotechnology company based in San Diego, California, discovering and developing
  first-in-class small-molecule drugs by targeting fundamental disease mechanisms it calls biological choke points. Its end-to-end
  GALILEO AI engine spans drug design, target discovery, and preclinical development, supported by specialized models including
  AmesNet for regulatory-grade toxicology prediction and ChemPrint for chemical property prediction. Lead programs target
  RdRp Thumb-1 (a conserved allosteric pocket on viral RNA-dependent RNA polymerase) and BRD4, with lead assets MDL-001, a
  broad-spectrum oral antiviral candidate, and MDL-4102. Surfaced as a portfolio company of 8vc and added to the API Evangelist
  network. As of this enrichment pass Model Medicines publishes no public API, developer portal, SDK, or documentation surface;
  its AI platform is used internally for drug discovery.
url: https://raw.githubusercontent.com/api-evangelist/model-medicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- 8vc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Drug Discovery
- Artificial Intelligence
- Pharmaceuticals
- Small Molecules
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/model-medicines-domain-security.yml
- type: Website
  url: https://modelmedicines.com
- type: PrivacyPolicy
  url: https://modelmedicines.com/privacy-policy
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1